MSB 6005
Alternative Names: MSB-6005Latest Information Update: 28 Apr 2024
At a glance
- Originator University of California, San Diego
- Developer MatriSys Bio
- Class Bacteria; Skin disorder therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Rosacea
- No development reported Netherton Syndrome
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Netherton-Syndrome in USA (Topical)
- 16 Mar 2021 Phase-I clinical trials in Netherton Syndrome in USA (Topical) before March 2021 (MatriSys Bioscience Pipeline, March 2021)
- 16 Mar 2021 Preclinical trials in Rosacea in USA (Topical) before March 2021 (MatriSys Bioscience Pipeline, March 2021)